摘要：Transitional cell carcinoma of the ovary is a relatively recently established entity. The pure form of transitional cell carcinoma (TCC) accounts for only 1% of surface epithelial tumours, mixed carcinomas with a predominant TCC component comprise 5% and those with a minor TCC component make up 3%.1,2 The major clinical impetus for accepting TCC as a distinct entity was provided by M.D. Anderson Cancer Centre’s finding that these carcinomas respond better to chemotherapy than most other surface epithelial cancers.3
Because of the positive outcome to chemotherapeutic agents it is mandatory to recognize this distinct morphologic type of ovarian cancer since these patients have a 5 year survival rate as high as 41%.1,4.
Loading...
